


RealRate

## PHARMACEUTICAL 2022

#### **THORNE®**

# Thorne Healthtech Inc. Rank 43 of 475





### PHARMACEUTICAL 2022



## Thorne Healthtech Inc. Rank 43 of 475

#### **THORNE®**

The relative strengths and weaknesses of Thorne Healthtech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Thorne Healthtech Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 604% points. The greatest weakness of Thorne Healthtech Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 273% points.

The company's Economic Capital Ratio, given in the ranking table, is 136%, being 412% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	101,259
Cost of Goods Sold	87,893
Intangible Assets	21,033
Liabilities, Current	25,737
Liabilities, Non-Current	27,606
Other Assets	25,977
Other Compr. Net Income	0
Other Expenses	27,164
Other Liabilities	3,625
Other Net Income	-2,495
Property and Equipment	27,030
Research and Development	5,936
Revenues	185,246
Selling, General and Administrative Expense	54,913

Output Variable	Value in 1000 USD
Assets	175,300
Liabilities	56,967
Expenses	175,906
Stockholders Equity	118,332
Net Income	6,845
Comprehensive Net Income	6,845
Economic Capital Ratio	136%